Video

Dr. Kremyanskaya on Effect of CPI-0610 in Patients With Myelofibrosis

Marina Kremyanskaya, MD, discusses the effect of CPI-0610 in patients with myelofibrosis.

Marina Kremyanskaya, MD, hematologist/oncologist at Mount Sinai Hospital, discusses the effect of CPI-0610 in patients with myelofibrosis.

In the MANIFEST trial, patients with myelofibrosis who are refractory to or intolerant of ruxolitinib (Jakafi) were treated with the BET inhibitor CPI-0610 in combination with ruxolitinib or CPI-0610 alone. Preclinical data with myelofibrosis models suggest that a combination of BET and JAK inhibitors can result in synergistic reduction of splenomegaly, bone marrow fibrosis, and improvement in anemia, says Kremyanskaya.

It is hopeful that this combination will demonstrate efficacy in the clinical setting, Kremyanskaya concludes.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center